Previous 10 | Next 10 |
Deciphera Pharmaceuticals (NASDAQ: DCPH ) +121% on positive late-stage ripretinib data . More news on: Deciphera Pharmaceuticals, Inc., DelMar Pharmaceuticals, Inc., Alcentra Capital Corporation, Stocks on the move, Read more ...
Thinly traded Deciphera Pharmaceuticals (NASDAQ: DCPH ) is up 101% premarket on increased volume in reaction to positive topline results from a 129-subject Phase 3 clinical trial, INVICTUS , evaluating ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients w...
- Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST – - Median Progression Free Survival (mPFS) Sustained across All Cohorts - - Additional Phase 1 Results Expected to be Presented at Upcoming Medical Meeting - -...
- INVICTUS Achieved Primary Endpoint, Ripretinib Significantly Improved Progression Free Survival (PFS) Versus Placebo in Patients with Fourth-line and Fourth-line Plus GIST - - Median PFS for Ripretinib of 6.3 Months Versus Placebo of 1.0 Month; Hazard Ratio of 0.15, p<0.0001- ...
Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q2 GAAP EPS of -$0.56 beats by $0.53 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Top-line Data from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Fourth-line and Fourth-line Plus Gastrointestinal Stromal Tumor (GIST) Patients Expected this Month - - Ripretinib Granted Fast Track Designation by the U.S. Food and Drug Administration for Treatment of Pati...
Idea Slides Introduction RET mutations are seen in ~2% of NSCLCs. Currently, there are no FDA-approved treatments for RET-mutated NSCLC. Multi-targeted drugs have been tested in these patients, but without much success. RET-targeted therapies like Blueprint Medicines' ( BPMC ) and L...
Note: This article was first revealed to subscribers to my exclusive marketplace, The Formula , in February when shares of Blueprint were trading < $80. Preface Documents: 10-Q | Company Slides Shares: 48,853,933 | PPS: $100 | Market Cap: $4.8B | Enterprise Value...
Outlook Therapeutics (NASDAQ: OTLK ) initiated with Buy rating and $8 (310% upside) at H.C. Wainwright. Shares up 11% premarket. More news on: Outlook Therapeutics, Inc., Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the mov...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the appointment of Susan L. Kelley, M.D. to its Board of Directors. Dr. Kelley will serve as an independent director and mem...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
2024-03-21 19:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-11 17:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK ® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 – – Expects to Submit NDA for Vimseltinib in the Second Quarter of 20...